Literature DB >> 1658131

Malignant hypertension.

P Kincaid-Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1658131

Source DB:  PubMed          Journal:  J Hypertens        ISSN： 0263-6352            Impact factor:   4.844


× No keyword cloud information.
  5 in total

1.  Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant nephrosclerosis model.

Authors:  Karen A Griffin; Aaron Polichnowski; Natalia Litbarg; Maria Picken; Manjeri A Venkatachalam; Anil K Bidani
Journal:  Hypertension       Date:  2014-06-23       Impact factor: 10.190

Review 2.  Secondary hypertension. An overview of its causes and management.

Authors:  D H Streeten; G H Anderson
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

Review 3.  Adverse effects of direct-acting vasodilators.

Authors:  P Armario; R Hernandez del Rey; H Pardell
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

4.  Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats.

Authors:  Šárka Jíchová; Libor Kopkan; Zuzana Husková; Šárka Doleželová; Jan Neckář; Petr Kujal; Zdenka Vernerová; Herbert J Kramer; Janusz Sadowski; Elzbieta Kompanowska-Jezierska; Rami N Reddy; John R Falck; John D Imig; Luděk Červenka
Journal:  J Hypertens       Date:  2016-10       Impact factor: 4.844

5.  20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats.

Authors:  Lenka Sedláková; Soňa Kikerlová; Zuzana Husková; Lenka Červenková; Věra Čertíková Chábová; Josef Zicha; John R Falck; John D Imig; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Vojtěch Krátký; Luděk Červenka; Libor Kopkan
Journal:  Biosci Rep       Date:  2018-09-12       Impact factor: 3.840
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.